Hady Samaha

Aug 28, 2023 | nature.com | Angela R. Branche |David J. Diemert |Susan J Little |Evan Anderson |Angelica C. Kottkamp |Anne F. Luetkemeyer | +19 more

AbstractVaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection wanes over time, requiring updated boosters. In a phase 2, open-label, randomized clinical trial with sequentially enrolled stages at 22 US sites, we assessed safety and immunogenicity of a second boost with monovalent or bivalent variant vaccines from mRNA and protein-based platforms targeting wild-type, Beta, Delta and Omicron BA.1 spike antigens.

Apr 4, 2023 | jci.org | Prabhu S Arunachalam |Lilin Lai |Hady Samaha |Yupeng Feng

AbstractBACKGROUND. Maintaining durable immunity to vaccination represents a major challenge, but whether booster mRNA vaccination improves durability is unknown. METHODS. We measured antibody responses in 55 healthy adults who received a booster dose of Pfizer-BioNTech or Moderna vaccine against SARS-CoV-2 and calculated the half-life of antibody titers. We also measured memory B and T cell responses in a subset of 28 participants.